Kirk Wilhelmsen
Overview
Explore the profile of Kirk Wilhelmsen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
753
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Keith C, Haut M, Teixeira C, Mehta R, Phelps H, Ward M, et al.
J Alzheimers Dis
. 2024 Dec;
102(3):778-791.
PMID: 39670736
Background: Alzheimer's disease (AD) is classically characterized by alterations in memory consolidation. With the advent of diagnostic biomarkers, some patients clinically diagnosed with AD display biomarkers inconsistent with the diagnosis....
2.
Scarisbrick D, Keith C, Teixeira C, Mehta R, Phelps H, Coleman M, et al.
Appl Neuropsychol Adult
. 2024 Aug;
:1-8.
PMID: 39140183
Introduction: Memory deficits are the primary symptom in amnestic Mild Cognitive Impairment (aMCI); however, executive function (EF) deficits are common. The current study examined EF in aMCI based upon amyloid...
3.
Keith C, Lindberg K, Wilhelmsen K, Mehta R, Teixeira C, Miller M, et al.
Cogn Behav Neurol
. 2024 Jul;
37(3):144-153.
PMID: 39069962
Background: While the cognitive hallmark of typical Alzheimer disease (AD) is impaired memory consolidation, increasing evidence suggests that the frontal lobes and associated executive functions are also impacted. Objective: We...
4.
Rezai A, DHaese P, Finomore V, Carpenter J, Ranjan M, Wilhelmsen K, et al.
N Engl J Med
. 2024 Jan;
390(1):55-62.
PMID: 38169490
Antiamyloid antibodies have been used to reduce cerebral amyloid-beta (Aβ) load in patients with Alzheimer's disease. We applied focused ultrasound with each of six monthly aducanumab infusions to temporarily open...
5.
Piamjariyakul U, McKenrick S, Smothers A, Giolzetti A, Melnick H, Beaver M, et al.
PLoS One
. 2024 Jan;
19(1):e0296438.
PMID: 38166130
Introduction: Older adults living alone in rural areas frequently experience health declines, social isolation, and limited access to services. To address these challenges, our medical academic university supported a quality...
6.
Coleman M, Keith C, Wilhelmsen K, Mehta R, Teixeira C, Miller M, et al.
Front Neurol
. 2023 Sep;
14:1214083.
PMID: 37731852
Composite cognitive measures in large-scale studies with biomarker data for amyloid and tau have been widely used to characterize Alzheimer's disease (AD). However, little is known about how the findings...
7.
Keith C, Haut M, Wilhelmsen K, Mehta R, Miller M, Navia R, et al.
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn
. 2022 Nov;
30(6):923-939.
PMID: 36367308
Alzheimer's disease is primarily known for deficits in learning and retaining new information. This has long been associated with pathological changes in the mesial temporal lobes. The role of the...
8.
Ocasio J, Babcock B, Malawsky D, Weir S, Loo L, Simon J, et al.
Nat Commun
. 2022 May;
13(1):3048.
PMID: 35618754
No abstract available.
9.
Keith C, McCuddy W, Lindberg K, Miller L, Bryant K, Mehta R, et al.
Neuropsychol Dev Cogn B Aging Neuropsychol Cogn
. 2022 May;
30(5):669-686.
PMID: 35603568
Amnestic mild cognitive impairment (aMCI) and Alzheimer's disease (AD) dementia are characterized by pathological changes to the medial temporal lobes, resulting in explicit learning and retention reductions. Studies demonstrate that...
10.
Van Buren E, Hu M, Cheng L, Wrobel J, Wilhelmsen K, Su L, et al.
Brief Bioinform
. 2022 Mar;
23(3).
PMID: 35325048
We propose TWO-SIGMA-G, a competitive gene set test for scRNA-seq data. TWO-SIGMA-G uses a mixed-effects regression model based on our previously published TWO-SIGMA to test for differential expression at the...